Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2013

View Archived Issues

Fedovapagon effectively reduces nocturia in men with BPH

ProQinase and Mercachem obtain E.U. funding

Israeli government renews funding to BioTime subsidiary

Medicago produces VLP vaccine candidate for H7N9 virus

Hisamitsu reports results from phase II study of terbinafine patch

Toyama Chemical obtains exclusive rights to solithromycin in Japan

Novel genomic model as a predictor of metastatic disease progression in prostate cancer

Potent novel anti-NS4B compounds from PTC Therapeutics

Improved pyrimidinediones for HIV infection described

Epigenetic modifications investigated in animal models of cancer

AbbVie and Alvine to collaborate on celiac disease therapeutic

Data monitoring board recommends continuation of phase III Livatag trial

FDA accepts supplemental BLA filing for Adcetris

TLR2 expression as a potential biomarker for clinical severity of atherosclerosis

Intercell and Vivalis to complete merger

Pearl Therapeutics begins phase III PT-003 program in moderate to severe COPD

Piramal Enterprises receives IND approval for P-11187

Rib-X begins phase III trial of Captisol-enabled delafloxacin

Sigma-Tau begins phase I study of heparanase inhibitor SST-000

Shionogi updates developments of fourth quarter of fiscal 2012

FDA approves Tarceva and accompanying test in NSCLC

Merck & Co. patents new OX1 and OX2 receptor antagonists

Novel arginase inhibitors disclosed by Mars, Inc.

BioTheryX synthesizes novel agents for cancer

BIKAM Pharmaceuticals presents new agents for ocular disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...